Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.38 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085857 | 1.00 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL6085855 | 1.00 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL7045582 | 0.84 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL6083485 | 0.84 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL6083497 | 0.84 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL6083489 | 0.84 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL6083831 | 0.81 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL6083828 | 0.81 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL6083852 | 0.81 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3PFKFB2PFKFB1 | |
| SCHEMBL6882391 | 0.80 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105516-B2 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| WO-2004026237-A2 | COMPOUNDS FOR THE TREATMENT OF PREMATURE EJACULATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | HTR5A, SLC18A2, CYP17A1 | SLC6A4 12/4885SLC6A2 30/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.